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Abstract 
Background: North Carolina has been hit hard by the opioid epidemic plaguing the United 
States. In 2015, 738 people in the state died of overdose on prescription opioids. Recent Centers 
for Disease Control and Prevention (CDC) data shows that in North Carolina, there are 
approximately 97 opioid prescriptions written per 100 people in the state.2 An important 
perspective on solving this crisis involves decreasing unsafe prescribing. In response, the North 
Carolina Medical Board has enacted several initiatives to decrease unsafe opioid prescribing by 
physicians and physician assistants in the state, including a new continuing medical education 
requirement for certain licensees, adoption of the CDC guideline on opioid prescribing, and a 
novel monitoring program called the Safe Opioid Prescribing Initiative. 
Purpose: The goal of this study is to characterize North Carolina Medical Board licensee 
attitudes toward each of the Board's three initiatives to detect and decrease unsafe opioid 
prescribing in the state.  
Methods: Letters, emails, and website correspondence submitted directly to the NCMB as well 
as online comments posted to NCMB newsletter articles pertaining to the three initiatives were 
analyzed. Comments posted to the articles were analyzed and coded as were the initial letters. 
Select items of interest were identified and recorded in a codebook, available in appendix 2. 
Demographic information related to the sender included origination of the letter (reply to an 
NCMB communication, or a letter that was originated by sender.) We also included the format of 
the communication, person or group sending the letter, and licensee specialty when provided. 
Content areas abstracted from each letter included letter tone, advocacy, and theme. Quantitative 
analysis was limited to calculating simple frequencies and percentages of demographic and 
content areas of interest.  
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Results: Forty-nine letters were obtained for analysis. The majority of articles (43) were 
comments left on the NCMB website in response to articles about SOPI, the new CME 
requirements, or the CDC guidelines. Most respondents did not sign with their credentials or 
indicate practice specialty in the body of their letter. The majority of the letters, 25 (51%) were 
solely negative, or critical of the policy that they referenced. 10 letters (20.4%) were positive, 
praising the policy. 2 letters (4.1%) were both positive and negative, presenting “pros and cons” 
of the policy. Nearly one quarter of letters 12(24.5%), however, had a tone that could not be 
determined. Respondents overwhelmingly advocated for the interests of themselves and their 
fellow licensees, with 35 letters (71.4%) addressing the concerns only of physicians.  Letter 
themes varied widely as well, with 35% providing alternative policy recommendations and 22% 
lamenting the added CME burden facing licensees. 16% represented praise for the policy being 
enacted. Fear of under prescribing, diminished access to patient care, and general policy 
discussion each received 8% of the references, with increased provider burnout and stress 
representing less than one percent.  
Conclusion: NCMB licensees have varying views on the initiatives that the Board has put forth 
to combat unsafe opioid prescribing. While the majority of communications were negative in 
tone, many responded with alternative policy recommendations, showing stakeholder 
engagement in the process. In order to optimize its connection to licensees, the Board must 
continue to communicate new opioid prescribing policies and refine them as necessary to prevent 
unsafe prescribing while protecting the practice of appropriate pain management.  
 
Background 
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 North Carolina has been hit hard by the opioid epidemic plaguing the United States. In 
2015, 738 people in the state died of overdose on prescription opioids.1 This death toll was larger 
than that of the deaths from heroin and cocaine combined.1 Recent CDC data show that in North 
Carolina, approximately 97 opioid prescriptions are written per 100 people in the state.2 
Nationally, of individuals who use prescription opioids, 55% obtain the pills free from a friend or 
relative, while 17% receive them from one physician.3 Therefore, one view on solving this crisis 
involves reducing irresponsible prescribing. While various state, local, and non-governmental 
agencies have adopted various roles to address prescribing, the North Carolina Medical Board is 
well positioned to take action. Charged with “properly regulating the practice of medicine and 
surgery for the benefit and protection of the people of North Carolina,” 4 the Board has enacted 
several initiatives to reduce unsafe opioid prescribing by physicians and physician assistants in 
the state, while accounting for the fact that the treatment of pain is essential to the practice of 
medicine.4 
In March 2016, the Board voted to change rules to their continuing medical education 
(CME) requirement, requiring mandatory opioid prescribing CME for all licensees who prescribe 
controlled substances beginning July 1, 2017. Under this policy, licensees must be able to show 
that for each 3 year CME cycle they have completed at least 3 hours of training related to safe 
opioid prescribing. There is no single mandatory course nor defined subject matter. Licensees are 
nor required to immediately document completion and report it to the board, but must be able to 
show evidence of completion upon audit or request. A 60 hour CME requirement per 3-year 
cycle is already in place. This new rule now designates that 5% of that total CME time must be 
dedicated to opioid education. North Carolina’s medical board is not the first state to implement 
such a policy. At least sixteen other boards require that their licensees complete varying hours of 
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continuing medical education related to prescribing controlled substances.5 One purpose of the 
present study is to determine licensee reaction to the policy in North Carolina in order to 
understand how these reactions may affect the future direction and overall survival of the policy.  
The second policy to be enacted was the creation of the Board’s novel “Safe Opioid 
Prescribing Initiative.” Enacted in April 2016, this monitoring initiative is designed to identify 
and appropriately discipline North Carolina Medical Board licensees who are found to be 
prescribing opioids in an unsafe or irresponsible manner. Licensees are selected for review if 
they meet at least one of three criteria:  the prescriber falls within the top one percent of licensees 
prescribing 100 morphine milligram equivalents (MME) per patient per day; or the prescriber is 
in the top one percent of those prescribing 100 MME with a benzodiazepine and falls within the 
top one percent of all controlled substance prescribers; or the licensee has had two patients die 
from opioid overdose within a span of twelve months. Prescribing information is provided to the 
board by the North Carolina Department of Health and Human Services. For the period between 
the program’s enactment in April 2016 through January 2017, the program resulted in the 
NCMB opening 62 cases on licensees, 54% of which resulted in action being taken by the Board; 
the remaining 46% of cases were closed with no formal action taken.6 Upon examining the 
records of licensees selected for review and the results of these investigations, the board has 
decided to make several changes to the selection criteria. They will expand the first two 
categories to cover the top two percent of those prescribing 100 MMEs instead of only one 
percent. To improve specificity for the opioid deaths criteria, the time period will now be 6 
months, with the stipulation that the prescribing physician had to prescribe at least 30 opioid 
tablets to the patient within 60 days of the patient’s death.7 The Board will be accepting public 
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comment on these rules until May 1, 2017. While awaiting an official rule change, the Board has 
begun to apply these rules internally during case reviews.  
Though the Board emphasized in  communications to licensees that the policy did not 
denote a limit to prescribing opioids, community feedback began to suggest that some physicians 
may have been treating it this way. Board staff reported fielding phone calls from patients 
complaining that their physician either drastically cut their opioid dose, discontinued prescribing 
opioids for their pain, or dismissed the patient from the practice altogether because of the 
“medical board’s new rule.” Though the initial program criteria should only have been likely to 
involve  0.2% of active licensees6 directly, the literature suggests that triggering medical board 
action remains a concern of some physicians who prescribe opioids.13 To address this concern, 
the board put together a presentation about SOPI that outlined the need for and details of the 
program. Board staff offered this presentation to hospitals, physician groups, educational 
institutions, or whomever requests more information about the policy. They even had meetings 
with individuals and groups in efforts to quell fears and further explain any details about which 
licensees were concerned. The Board, however, continued to receive calls and letters. Given that 
SOPI  is a new program, continually being refined to meet optimal goals, it can benefit from a 
systematic initial evaluation of stakeholder reaction.  
The third step the NCMB took was its decision to phase out its comprehensive opioid 
prescribing policy in favor of adopting the Centers for Disease Control’s Guideline for 
Prescribing Opioids for Chronic Pain. Published in March 2016, this set of guidelines, designed 
mainly to address opioid prescribing in the primary care setting, lays forth a series of suggested 
steps and principles that providers can follow when deciding to use opioid analgesics to treat a 
patient’s non-cancer pain.8 These guidelines have been endorsed or supported by various entities, 
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such as professional medical societies, state health and justice departments, and medical 
regulatory boards.9,10,11 The guidelines themselves, however, are not without controversy. Some 
groups have cited the lack of strong evidence to support some of the recommendations put forth 
in the guidelines, such as setting thresholds on strength of medicine to be prescribed and duration 
of treatment for acute pain.12 This study also seeks to characterize licensee reaction to these 
guidelines.  
 
Methods 
  
I obtained licensee feedback on the Board’s prescribing policies from two sources. The 
Medical Board Communications Director provided me with correspondence from licensees sent 
via email, regular US postal mail, and as comments submitted directly through the NCMB 
website. I obtained additional correspondence by searching the NCMB website for comments 
submitted in response to articles in the NCMB’s quarterly newsletter, the “Forum” pertaining to 
the SOPI initiative, the CME requirement, and adoption of the CDC opioid prescribing 
guidelines. All letters provided by the communications director were analyzed at the NCMB 
offices in Raleigh, NC. Letters were kept behind at least 2 locked doors at all times. Due to a 
confidentiality agreement in place with the NC Medical Board, I was the only individual able to 
see the letters that came from this source. I did not record any identifying information about 
licensees from this source.  
All coding and letter analysis was performed by me, in conformity with the NCMB 
confidentiality procedures I agreed to. The University of North Carolina Institutional Review 
Board for Human Subjects Research determined that the study is “not human subjects research,” 
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as defined under federal regulations [45 CFR 46.102 (d or f) and 21 CFR 56.102(c)(e)(l)], and 
does not, thus, require IRB approval (UNC IRB study # 17-0388).  
 I searched all past issues of “The Forum” were searched for articles pertaining to the Safe 
Opioid Prescribing Initiative, the opioid prescribing CME requirement, and the Board’s decision 
to adopt the CDC guidelines and then printed out and numbered reader comments posted at the 
end of all the identified articles. I then coded and analyzed the comments exactly as I had the 
NCMB board correspondence (see below and in Appendix 2). As the names and content of these 
letters are publicly available on the NCMB website, there was no need for strict confidentiality 
procedures, but I did not code any identifying information.  
I selected items of interest from all communications and recorded them in a codebook, 
available in Appendix 2. Demographic information related to the sender included origination of 
the letter (reply to an NCMB communication, or a letter or comment originated by the sender.) I 
also coded the format of the communication, person or group sending the letter, and licensee 
specialty when that information was included in the communication.  
 The content areas I abstracted from each letter included letter tone, advocacy, and theme. 
“Tone” encompassed whether the letter or comment was positive (in favor or support of the 
policy), negative (against the policy) or both positive and negative. “Advocacy” was defined as 
whether the letter/comment represented the interest of patients, physicians, or both. I coded eight 
possible themes for letters/comments, including fear that the policy would lead to under-
prescribing of opioids, fear that physicians would acquire a history of medical board action, that 
the policy would result in patients’ diminished access to care, or added and undue CME burden. 
Other themes included general policy discussions, praising the policy, or providing alternative 
policy recommendations. I coded up to three themes for each letter and comment. Each variable 
9	  
	  
allowed for a value of “not ascertainable” when letters were either too short or too vague in their 
messaging to determine an overall tone, clear direction of advocacy, or theme.  
 I coded a total of 49 communications which generated and 51 distinct, analyzable 
subjects.  I coded all data in a single Microsoft Excel spreadsheet, which was also used to 
calculate frequencies and percentages of demographic characteristics and content areas of 
interest. The small N of cases in this early evaluation of reactions to the Board’s policy 
precluded the use of inferential statistics and limited analysis to a discussion of simple 
frequencies and percentages of demographic and content areas of interest. This resulted in a 
descriptive study at this early stage of policy implementation, but the structure of the codebook 
would allow for more complex analysis, should the Board decide to continue coding responses 
over time.  
 
Results 
  
Forty-nine letters were obtained for analysis. All but one was originally in electronic 
format. Four letters were originated by the sender, whereas 45 were responses to NCMB 
communications. The majority of licensee responses were comments left on the NCMB website 
in response to articles about SOPI, the new CME requirements, or the CDC guidelines. (Figure 
1) One was a typed letter, nine were emails, and three were transmitted via the “contact us” form 
on the NCMB website. All but one letter were sent by individual licensees, while one was signed 
by a group of physicians from a single practice. Most respondents did not sign with their 
credentials or indicate practice specialty in the body of their letter. Thirty-four did not designate 
their specialty. Two respondents self-identified as general surgeons, and two as orthopaedic 
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surgeons. One letter each came from physicians practicing pain management, radiology, general 
practice, pathology, anesthesiology, emergency medicine, and ophthalmology. One licensee self-
identified as a physician assistant.  
 Although there were 49 unique communications, some referenced more than one topic, 
yielding a total of 51 distinct policy references. In terms of subject area, the CME requirements 
elicited the most feedback, with 63% of references being to this policy. Fourteen references 
(27%) were about the Safe Opioid Prescribing Initiative, and 5 references (10%) commented on 
the Board’s adoption of the CDC Opioid prescribing guidelines. Because so few communications 
addressed the CDC guidelines, I cannot comment meaningfully on the overall licensee response 
to this policy. 
 I devoted particular attention to coding the tone of the letters the board received. The 
majority of the letters, 25 (51%), were solely negative about or critical of the policy they 
addressed. Ten letters (20.4%) were positive, praising the policy. Two letters (4.1%) were both 
positive and negative, presenting “pros and cons” of the policy. Nearly one quarter of letters, 
12(24.5%), however, had a tone I could not ascertain. Many of these letters neither praised nor 
criticized the various policies, but provided words of caution or alternative policy 
recommendations. Tone differed widely across the different types of letters. (Figure 2)  
The table makes clear that, thus far in the policies’ early history, the SOPI program  has attracted 
less negative attention than has the CME requirement.  The adoption of the CDC guidelines has 
attracted the smallest number of comments to date.  
 Respondents overwhelmingly advocated for the interests of themselves and their fellow 
licensees, with 35 letters (71.4%) addressing the concerns only of physicians. (Figure 3) Five 
letters (10%) were neutral responses based on the policy rather than advocating for the groups 
11	  
	  
affected by it. When analyzed by letter topic, advocacy trends between groups appeared 
consistent with subject matter. Physician advocacy dominated the SOPI and CME letter groups, 
with solely physician interests accounting for 57% and 88% of advocacy, respectively. SOPI 
letters did have the largest percentage of references to patients, with 36% (of 14 letters) 
representing the interests of patients and physicians or patients alone. Of the five letters 
referencing the CDC guidelines, two advocated for physician interests, one for both physicians 
and patients, none for solely patients, and two were unascertainable. 
 The 49 letters exhibited a diverse group of themes. As was the case with topics, letters 
were capable of presenting more than one theme, such that licensees offered total of 63 discrete 
themes in all the letters. The themes are represented in Figure 4. Twenty-two references (35%) 
provided alternative policy recommendations. Aside from licensees referencing the increased 
CME burden, the two themes referenced the most were alternative policy recommendations and 
outright praise for a policy, showing that despite a small majority of letters having a negative 
tone, a substantial portion of licensee comments reflect support for the Board’s activities. Of 
note, two themes that have been previously documented in opioid policy literature, fear of under-
prescribing and diminished access to patient care, represented only a small portion of licensee 
concerns.  
 Prevailing themes differed by letter topic. The most common themes represented in SOPI 
letters were fear that the policy would result in underprescribing of opioids even when 
prescribing them would be appropriate; alternative policy recommendations; and praise for the 
policy. These, combined, represented 76% of the themes in the SOPI comments, with praise for 
the policy representing 24%. For CME letters, concerns about an added CME burden and 
alternative policy recommendations accounted for 76% of the themes, with a slightly higher 
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representation for alternative policy recommendations. For the CDC guideline letters, 56% of 
responses were praise for the policy and alternative recommendations. For each of the topics, 
however, provider burnout, diminished access to patient care, and general policy discussions 
were all mentioned at least once.   
 
Discussion 
 
Much information can be gained from the results of this small yet important study. 
Regarding SOPI, though nearly one fourth of the letter themes reflected praise for the policy, the 
initiative elicited a large number of negative responses, with respondents primarily concerned 
that the measure would result in physicians failing to prescribe opioids in order to avoid board 
action, even when such prescriptions were appropriate, thus harming patients. The argument can 
be made, however, that it is better for physicians and physician assistants to be regulated, 
monitored, and disciplined by a board of their peers who share a similar background and 
understanding of medical principles than by groups largely composed of nonmedical individuals, 
such as state legislatures and justice departments. Gilson et all showed that when given the 
choice of actions taken by health regulatory boards and those taken by legislators, health 
regulatory boards are more likely to use language in their policies that promote treatment of pain 
and less likely to contain measures that arbitrarily restrict prescribing or require expert 
consultation, both of which are widely viewed as barriers to effective pain management.13 While 
SOPI is being refined by the Medical Board, the North Carolina Legislature is taking its own 
steps to combat the opioid crisis. House Bill 243, currently before the legislature and known as 
the Strengthen Opioid Misuse Prevention or “STOP” act, aims to slash the number of opioid 
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prescriptions by imposing the very measures that Gibson et al determined to be discouraging of 
optimal pain management. The bill mandates limiting the duration of prescriptions for acute pain 
for 5 - 7 days, requiring that physician assistants and nurse practitioners consult with a 
supervising physician before prescribing for a patient over 30 days, and mandates registration 
and use of the North Carolina Controlled Substances Reporting System.14  It would be interesting 
to note whether NCMB licensees, if given the chance, would embrace or acquiesce to SOPI to 
avoid the much more imposing rules proposed by the legislature.  
 In a review of state medical board opioid policies and initiatives, I was unable to locate 
another state with a similar monitoring policy. The only other state that mentions any specific 
MME threshold of any kind is the state of Ohio, whose board endorses an 80 MME “cutoff.”15 
Once prescribers meet this point, rather than triggering a board investigative process, prescribers 
are simply encouraged to take a step back and re-evaluate the patient, treatment plan, and goals, 
then make a decision whether to continue opioid treatment or refer to specialty care.15 While this 
would possibly alleviate some of the concerns about board action and provider burnout 
expressed by NCMB licensees, it may still create a sense of a virtual “limit” above which some 
physicians may be hesitant to prescribe, leading to the similar result of under prescribing.  
Overall response to the CME requirement was negative, with a large number of licensees 
remarking that this new requirement would result in an added, unnecessary and unhelpful CME 
burden, especially for physicians who do not prescribe opioids. One positive note that came from 
the letters, however, was that many licensees did not simply criticize the policy, but also offered 
recommendations on how to improve it, some of which, the Board has gone on to implement. 
For example, a recurring theme from some letters was that if the Board was going to implement 
this policy, it should make the courses free and easily available to licensees on the Board 
14	  
	  
website, to facilitate compliance with the least amount of added work for licensees. The Board 
did, in fact do this.  
 Some opioid prescribing CME initiatives have shown to be helpful to clinicians.16 Boston 
University’s Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program is a 3 
hour course on safe opioid prescribing. Follow up assessments of clinicians who received the 
training showed an increase in their knowledge, confidence, and clinical practice in safe opioid 
prescribing. Perhaps one key to a successful CME initiative lies in finding programs from which 
licensees can derive the most benefit.  
Among state medical boards nationwide who require chronic pain and opioid CME, there 
is large variability in terms of the hours and types of course required as well as the physicians 
who must take the course. Some states, such as Florida  and Ohio, only require this training for 
operators of or physicians working in registered pain clinics.5 Iowa, however requires two hours 
of chronic pain CME for all primary care physicians.5 West Virginia requires 50 hours of CME 
every two years, 3 hours of which must be related to controlled substances, and the courses must 
be those that are already approved by the Board.5 In this sense, North Carolina’s requirement is 
not the most burdensome, nor is it the most restrictive, but likely falls near the median in terms 
of flexibility and time commitment. Based on feedback from the NCMB licensees, it may be 
important to consider ease of access to courses, and tailoring the courses to the prescribers who 
can actually benefit the most from them.  
This study has several important limitations. As written communications were the only 
source of data for analysis, we excluded one source of potentially informative information – 
phone calls to the NCMB by both physicians and patients. NCMB staff state that they did receive 
a significant volume of phone calls from patients. Some called to complain that their physicians 
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had stopped prescribing them their previous doses of opioids or dismissed them from their 
practice altogether as a result of the new opioid rule. While this is not, in fact, board policy, there 
were reports of its occurrence. Though staff have repeatedly stressed to patients and licensees 
that this was not, in fact, a result of board policy, it speaks to one of the concerns that the rule 
will cause under prescribing and diminished access to care for some patients.  
 I relied on one NCMB staff member who receives communications from licensees and 
the public to collect these letters and make them available for review.  The Board had not 
heretofore had a particular system for archiving these communications. It is reasonable to assume 
that, in fact, I did not obtain all letters and that I may have an unrepresentative sample, and not 
the universe, of all written correspondence received by the Board. If this is the case, I could be 
missing some concerns.  One recommendation emerging from this study is that the Board may 
consider routinely logging and coding every such communication.   
 My sample of letters represents only a portion of letters that licensees chose to write, 
reflecting views of individuals who chose to actively communicate with the board. I cannot 
assume that the sample of written letters and comments reflects the opinions and beliefs held by 
all board licensees. 
 The overall sample size was quite small. The NCMB represents over thirty thousand 
physician and physician assistant licensees. Our sample size of 49 letters represents a fraction of 
one percent of board licensees affected by these policies. Given this and the fact that our sample 
may not have included all of the written correspondence, it is difficult to make the argument that 
the results of this study will be generalizable to the entre body of NCMB licensees.  
 Although it is important to consider this study’s limitations, they should not invalidate its 
results. Though the sample size was small, I know of no particular way in which it is incomplete, 
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and getting letters or comments from every written communication venue available at the Board 
means I have a wider variety of sources and subjects. Even with the small sample size, some 
themes did recur frequently, and are worthy of additional attention. For example, while licensees 
had varied responses to SOPI and the adoption of the CDC guidelines, the tone of the letters 
about the CME requirement was overwhelmingly negative. For the reasons mentioned above, it 
cannot be said that this was the opinion of all or most licensees who were made aware of the 
requirement, but it certainly warrants further investigation.  
 If nothing more, the results of this small, initial evaluation could serve as a starting point 
from which the board can conduct a larger, more in depth review of correspondence. As many 
licensees also responded with alternative policy recommendations, the board may also take some 
of those recommendations into consideration. 
 
Conclusion 
 
The American opioid epidemic continues to garner more attention, and entities from all 
levels of the public and private sectors are continuing to come up with ways to address the 
problem.  
Many states have adopted CME guidelines, mandatory CSRS registration and use, and 
other interventions. The Safe Opioid Prescribing Initiative, however, is a novel program that 
continues to develop. The Board should carefully evaluate the feedback it receives as it refines 
policy criteria, more physicians are disciplined, and opioid prescribing patterns change. We 
should also watch to determine whether other state boards adopt similar measures. North 
Carolina, as do other states, illustrates how state legislatures may choose to act, oftentimes 
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regardless of what health regulatory boards do. The evidence suggests that health regulatory 
board policies are often less harsh and restrictive toward healthcare providers than is legislative 
intervention.13 This means that it will be important for medical regulatory boards to guide the 
process, acting in a way that protects the public from unsafe prescribing, while not unduly 
burdening their own licensees and promoting medically appropriate practice.  
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Appendix 1: Limited Systematic Review 
 
Over the past two years, the North Carolina Medical Board has adopted new policies to 
combat inappropriate opioid prescribing and rising opioid overdose deaths in North Carolina. 
Some initiatives, including mandatory continuing medical education about opioid prescribing for 
all licensees who prescribe controlled substances, is similar to policies in other states. Another, 
the implementation of the Safe Opioid Prescribing Initiative, is a novel approach to this 
persistent problem. To gain a better understanding of the role and effectiveness of state medical 
boards in addressing the opioid epidemic, I conducted a limited systematic review of published 
medical literature aimed at answering the following question:  Among all US states with medical 
regulatory boards, do state medical board opioid prescribing policies compared with legislative 
or no regulatory policy affect physician attitudes about opioids, opioid prescribing practices, or 
opioid overdose deaths in their respective states? 
A search of PubMED database using the terms “state medical board” and “opioid” was 
performed on March 27, 2017 at 10:47 pm. MeSH terms included opioid, regulation, and 
medical board. In order to be included, studies had to reference state medical board regulatory 
efforts, be available in English, and pertain to board regulation of opioids and controlled 
substances. Exclusion criteria were non-English language articles, no references to state board 
policy surrounding opioids or controlled substances, and the resource being unavailable through 
UNC libraries.  
The PubMED search yielded 39 results, of which 21 referenced state medical boards and 
opioid prescribing. An additional two studies were found in the reference section of included 
studies. The full text of each of these articles was reviewed. Seventeen of these studies met 
inclusion criteria. One of the original twenty articles was excluded because it was not available 
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from UNC libraries. An additional three were excluded because they did not address state 
medical board regulatory efforts in relation to opioid prescribing.   
 Of the sixteen included studies, three were historical analysis of the development and 
implementation of various Board and Federation of State Medical Board policies over the past 
years. Seven were analyses of various policies and programs that had been implemented. One 
was an interview with the president of a state board discussing his board’s specific policies and 
procedures. One was an editorial in response to a historical analysis, and three were studies (one 
initial and two follow up) on board member attitudes surrounding opioids and opioid policy. One 
was a systematic review on the effect of regulatory policy on opioid prescribing and opioid 
overdose.  
Four articles noted the strong role of medical boards in providing regulation and 
oversight in the area of oversight, and advocated for the use of medical board policies over 
legislative statutes to regulate opioid prescribing. One study, the systematic review, addressed 
the association between regulatory policies and effect on opioid overdose deaths, found 
insufficient evidence of association, and concluded that more studies are needed in this area. 
Eight articles covered the changes in state medical board regulatory policy over time, and found 
that policies have evolved with the changing epidemic, and are becoming more positive in 
language and promoting adequate, appropriate pain management while adopting policies that aim 
to decrease diversion and inappropriate prescribing.  
In conclusion, there is a shortage of evidence linking state board regulatory policy 
directly with opioid overdose rates. There is, however, strong support for medical board 
regulation over legislative or judicial regulation of opioids prescribing, due in part to more 
positive language in board policies as well as influence of medical board over physician’s ability 
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to practice. As data collection methods on opioids prescribing improves and medical boards 
adopt new policies, it is important for boards to track the effect that their policies have on both 
physician and patient centered opioid outcomes in their states.  
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Appendix 2: Data Collection Sheet 
   
 
 
*Note: This image represents is a part of a larger portion of the data collection sheet 
